Page last updated: 2024-11-12

4-(1-phenylethyl)resorcinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(1-phenylethyl)resorcinol: a depigmenting agent for treatment of solar lentigines; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11171903
CHEMBL ID3961037
SCHEMBL ID369337
MeSH IDM000614540

Synonyms (40)

Synonym
4-(1-phenylethyl)benzene-1,3-diol
unii-g37ufg162o
g37ufg162o ,
symwhite 377
1,3-benzenediol, 4-(1-phenylethyl)-
(+/-)-phenylethyl resorcinol
1,3-benzenediol, 4-(1-phenylethyl)-, (+/-)
phenylethyl resorcinol, (+/-)
phenylethyl resorcinol
85-27-8
AKOS017343138
symwhite 377 (phenyl ethyl resorcinol)
phenylethyl resorcinol [inci]
phenylethyl resorcinol, (+/-)-
1,3-benzenediol, 4-(1-phenylethyl)-, (+/-)-
SCHEMBL369337
4-(alpha-methylbenzyl)resorcinol
4-(1-phenylethyl)resorcinol
M2754
4-(1-phenylethyl)-1,3-benzenediol
2,4-dihydroxydiphenylethane
mfcd21648466
bdbm240731
us9422261, 4-(1- phenylethyl) benzene-1,3- diol
A863626
FT-0717569
DS-8462
4-((c) paragraph sign-methylbenzyl)resorcinol pound>>4-(alpha-methylbenzyl)resorcinol pound>>1,3-benzenediol, 4-(1-phenylethyl)-
BCP08432
DB14120
CHEMBL3961037
AMY14169
D78256
Q27278684
DTXSID501005319
AU-004/43508421
SY056470
CS-0099447
EN300-7418385
HY-125809

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The treatment was well tolerated, and no serious adverse effects were reported."( Clinical efficacy and safety of nano-microneedle-assisted phenylethyl resorcinol for the treatment of infraorbital dark circles.
Chen, HD; Li, YH; Xu, XG; Yu, CQ, 2021
)
0.62
"PR combined with nano-microneedle could be an effective and safe method for infraorbital DC."( Clinical efficacy and safety of nano-microneedle-assisted phenylethyl resorcinol for the treatment of infraorbital dark circles.
Chen, HD; Li, YH; Xu, XG; Yu, CQ, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TyrosinaseHomo sapiens (human)IC50 (µMol)131.00000.02304.459310.0000AID1717717
TyrosinaseHomo sapiens (human)Ki24.00001.70004.73339.1000AID1717709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
melanin biosynthetic process from tyrosineTyrosinaseHomo sapiens (human)
eye pigment biosynthetic processTyrosinaseHomo sapiens (human)
visual perceptionTyrosinaseHomo sapiens (human)
cell population proliferationTyrosinaseHomo sapiens (human)
response to UVTyrosinaseHomo sapiens (human)
response to blue lightTyrosinaseHomo sapiens (human)
response to vitamin DTyrosinaseHomo sapiens (human)
melanin biosynthetic processTyrosinaseHomo sapiens (human)
thymus developmentTyrosinaseHomo sapiens (human)
response to cAMPTyrosinaseHomo sapiens (human)
pigmentationTyrosinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
tyrosinase activityTyrosinaseHomo sapiens (human)
copper ion bindingTyrosinaseHomo sapiens (human)
protein bindingTyrosinaseHomo sapiens (human)
identical protein bindingTyrosinaseHomo sapiens (human)
protein homodimerization activityTyrosinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
cytoplasmTyrosinaseHomo sapiens (human)
lysosomeTyrosinaseHomo sapiens (human)
Golgi-associated vesicleTyrosinaseHomo sapiens (human)
melanosome membraneTyrosinaseHomo sapiens (human)
melanosomeTyrosinaseHomo sapiens (human)
intracellular membrane-bounded organelleTyrosinaseHomo sapiens (human)
perinuclear region of cytoplasmTyrosinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1717709Inhibition of human His-tagged tyrosinase expressed in HEK 293 cells using L-DOPA as substrate by Lineweaver-Burk plot analysis2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID1717717Inhibition of human His-tagged tyrosinase expressed in HEK 293 cells using L-DOPA as substrate by MBTH based assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID1717718Inhibition of mushroom tyrosinase using L-tyrosine as substrate by spectrophotometric method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (76.92)24.3611
2020's3 (23.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.98 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.14%)5.53%
Reviews1 (7.14%)6.00%
Case Studies2 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other10 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]